After mulling a potential buyout for a month, Freeline Therapeutics has decided that its future lies in the arms of its majority shareholder. London-based investment firm Syncona will pay $6.50 for each remaining American depositary share of the British biotech that it doesn’t already own—equivalent to a 51% premium on the company’s share price before it first extended the offer. Source: Fierce Biotech 22/11/2023